NLRC4 and neurodegenerative disease: Given clinical advancement of NLRP3 inhibitors in neurodegenerative disease, we questioned whether NLRP3 inhibition is sufficient to mitigate cytokine release and pyroptosis downstream of other inflammasomes such as NLRC4.